Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, +81

The Lancet Oncology

Cutaneous T-cell LymphomaLymphoid NeoplasiaMedicinePathologyMogamulizumab Versus Vorinostat +4

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, +17

The Lancet Oncology

Lymphoid NeoplasiaBispecific AntibodyMedicineImmunologyImmune Checkpoint Inhibitor +5

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Michael Wang, Wojciech Jurczak, Mats Jerkeman, +28

New England Journal of Medicine

Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study

Wojciech Jurczak, Ilídia Moreira, Govind Babu Kanakasetty, +13

The Lancet Haematology

Lymphoid NeoplasiaRituximab BiosimilarOncologyAdvanced Follicular LymphomaReference Rituximab +6

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, +21

Blood Advances

Hematological MalignancyRheumatologyLymphoid NeoplasiaHealth SciencesMedicine +13

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, +18

Blood

<i>TP53</i>mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Devendra Hiwase, Christopher N Hahn, Elizabeth Ngoc Hoa Tran, +38

Blood

ImmunohematologyCancer PathologyPathologyGenetic MedicineTumor Biology +22

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Matthew J. Matasar, Chan Y. Cheah, Dok Hyun Yoon, +17

Blood

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, +18

Blood

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, +16

Blood